Loading...
neuroinflammation suppression→dopaminergic pathway modulation
Statins' anti-inflammatory and antioxidant properties may ameliorate neuroinflammation implicated in schizophrenia, and simvastatin has been specifically investigated for symptom improvement. Evidence includes narrative reviews and early clinical trials, though data are preliminary and primarily observational. This represents a genuinely novel repurposing candidate with emerging mechanistic rationale.
“In this narrative review, we have investigated the effects of statin therapy in individuals suffering from major depressive disorder (MDD), schizophrenia, anxiety, obsessive-compulsive disorder (OCD), bipolar disorder (BD), delirium, and autism spectrum disorders using a broad online search of elect”
— Update on Statin Treatment in Patients with Neuropsychiatric Disorders. (2021)DOI“Statins exert anti-inflammatory and antioxidant effects and may be effective in improving the symptoms of schizophrenia.”
— Statins as an adjuvant therapy for patients with schizophrenia: An up-to-date systematic review and meta-analysis. (2024)DOI“Introduction: Statins such as simvastatin are recently introduced as agents that may have beneficial effects in schizophrenia regarding their prominent anti-inflammatory properties.”
— Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial (2021)DOI“Statins as an adjuvant therapy for patients with schizophrenia: An up-to-date systematic review and meta-analysis.”
— Statins as an adjuvant therapy for patients with schizophrenia: An up-to-date systematic review and meta-analysis. (2024)DOI“A meta-analysis on changes in total PANSS scores in studies on statins in schizophrenia, including the present study together with six other studies showed a significant improvement for statins compared to placebo (Hedges' G of -0.245 (CI= -0.403, -0.086, p = 0.002).”
— A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder. (2023)DOI“Lipid-modifying agents, particularly statins and fibrates, reduce the risk of mortality in people with schizophrenia.”
— Lipid-modifying agents and risk of all-cause, natural and suicide mortality in schizophrenia: nationwide cohort study. (2024)DOI“HMG-CoA reductase inhibitors (statins) versus placebo for people with schizophrenia.”
— HMG-CoA reductase inhibitors (statins) versus placebo for people with schizophrenia. (2025)DOI“Given the immune and kynurenine activation in bipolar disorder (BD) and schizophrenia, as well as the immune-modulatory effects of statins, we aimed to compare the relative risk (RRs) of psychiatric hospitalizations and ED visits between individuals prescribed lipophilic vs. hydrophilic statins vs. ”
— Lipophilic vs. hydrophilic statins and psychiatric hospitalizations and emergency room visits in US Veterans with schizophrenia and bipolar disorder. (2021)DOI